The Digital Transformation of Clinical Research
Clinical research is undergoing a fundamental transformation driven by wearable technology. The traditional model—periodic site visits, patient-reported outcomes, and retrospective data collection—is being replaced by continuous, objective, real-world data capture. Smart rings, with their 24/7 wearability, multi-parameter sensing, and minimal patient burden, are emerging as a powerful tool in this transformation.
The pharmaceutical industry spends over 00 billion annually on R&D, with clinical trials representing the largest cost component. The Tufts Center for the Study of Drug Development estimates that the average Phase III trial costs 55 million and takes 7-8 years from protocol design to regulatory submission. Wearable technology promises to reduce these costs by enabling smaller sample sizes (through more precise endpoints), shorter timelines (through continuous rather than episodic data), and improved patient retention (through reduced site visit burden).
This article examines how smart rings are being deployed in clinical research, the types of digital biomarkers they can capture, the regulatory considerations for using ring-derived data in regulatory submissions, and the OEM smart ring customization options for pharmaceutical companies, contract research organizations (CROs), and academic research institutions.
Digital Biomarkers: What Smart Rings Can Measure for Research
Digital biomarkers—objective, quantifiable physiological and behavioral data collected by digital devices—are the foundation of wearable-enabled clinical research. Smart rings can capture a rich set of digital biomarkers that are relevant across therapeutic areas.
Cardiovascular digital biomarkers include heart rate (resting, maximum, recovery), heart rate variability (SDNN, RMSSD, LF/HF ratio), and derived metrics such as cardiovascular fitness (VO2max estimation). These biomarkers are relevant for trials in heart failure, hypertension, atrial fibrillation, and post-myocardial infarction rehabilitation. A 2024 study in the European Heart Journal demonstrated that smart ring-derived HRV metrics predicted heart failure decompensation with 82% sensitivity, enabling earlier intervention than standard care.
Sleep digital biomarkers derived from smart ring PPG and accelerometer data include total sleep time, sleep efficiency, sleep onset latency, wake after sleep onset (WASO), and sleep stage distribution (light, deep, REM). These biomarkers are critical for trials in insomnia, sleep apnea, circadian rhythm disorders, and neurodegenerative diseases where sleep disruption is both a symptom and a progression marker. The FDA has qualified several sleep endpoints derived from wearable devices for use in clinical trials through the Drug Development Tool qualification program.
Activity and mobility digital biomarkers—step count, activity intensity, sedentary time, gait parameters—are relevant across virtually all therapeutic areas. In oncology trials, activity levels correlate with performance status (ECOG score) and quality of life. In neurology trials for Parkinson’s disease, gait parameters derived from accelerometer data can detect motor fluctuations and quantify treatment response. The European Medicines Agency has published guidance on the use of digital mobility outcomes in regulatory submissions for neurodegenerative disease therapies.
Temperature digital biomarkers from smart ring skin temperature sensors enable continuous rather than episodic temperature monitoring. This is particularly relevant for trials in infectious disease (fever monitoring), women’s health (ovulation tracking, menopausal symptom assessment), and inflammatory conditions where temperature fluctuations reflect disease activity.
Real-World Data Collection: Advantages of the Ring Form Factor
Smart rings offer distinct advantages over other wearable form factors for clinical research data collection. The 24/7 wearability is the most important: unlike wrist-worn devices that patients remove for charging, sleeping, or aesthetic reasons, rings are worn continuously, maximizing data completeness. A 2023 study comparing smart ring versus smartwatch adherence in a clinical trial setting found that ring wearers achieved 92% data completeness versus 78% for smartwatch wearers, a difference that substantially impacts statistical power.
The finger measurement site provides superior PPG signal quality compared to the wrist. The finger has denser vasculature, less motion artifact, and fewer anatomical variations that interfere with optical sensing. This translates into more accurate heart rate, SpO2, and HRV measurements—critical for clinical endpoints where measurement error directly reduces statistical power and increases required sample size.
The minimal patient burden of smart rings improves retention in longitudinal studies. A wearable that requires no behavioral change—put it on once and forget about it—achieves higher long-term adherence than devices that require daily charging, regular cleaning, or conscious effort to wear. In multi-year observational studies, where patient dropout is a major threat to data quality, the ring’s low-friction user experience is a significant advantage.
Patient Recruitment and Engagement: The Ring as a Recruitment Tool
Patient recruitment is the single greatest challenge in clinical research, with 80% of trials failing to meet enrollment timelines. Smart rings can serve as both a recruitment incentive and a screening tool.
As a recruitment incentive, the smart ring’s consumer appeal differentiates clinical trial participation. Patients are more willing to enroll in a trial that provides a sleek, modern device they can continue using after the study than one that requires cumbersome equipment and frequent site visits. The ring’s perceived value—both as a health monitoring tool and a lifestyle accessory—enhances the patient value proposition of trial participation.
As a screening tool, smart rings enable digital phenotyping—identifying potential trial participants based on passively collected physiological data. A pharmaceutical company developing a heart failure therapy could partner with a health system to deploy smart rings to a broad patient population, using the ring-derived data to identify patients with heart rate variability patterns consistent with early-stage heart failure who would be eligible for the trial. This targeted recruitment approach is more efficient than traditional mass advertising and chart review.
For CROs managing multiple trials, a fleet of smart rings can be provisioned and re-provisioned across studies. The OEM partner should provide a device management platform that supports bulk provisioning, firmware updates, and data collection configuration for multi-site, multi-study deployments. Smart ring customization for CRO use includes branding the device management dashboard with the CRO’s identity and integrating with the CRO’s existing clinical trial management systems (CTMS).
Longitudinal Study Design: Protocol Considerations
Designing a clinical study that incorporates smart ring data requires careful attention to protocol design, endpoint selection, and statistical analysis planning. The FDA’s Digital Health Center of Excellence has published guidance on the use of digital health technologies in clinical investigations, and this guidance should inform protocol development.
Endpoint selection is the most critical protocol decision. A digital biomarker measured by a smart ring can serve as a primary endpoint, a secondary endpoint, or an exploratory endpoint. Primary endpoints require the strongest evidence of analytical validity (does the device measure what it claims to measure?) and clinical validity (does the measurement correlate with clinical outcomes?). The FDA’s Clinical Outcome Assessment (COA) qualification program provides a pathway for obtaining regulatory acceptance of digital endpoints.
Data collection frequency and duration must be specified in the protocol. Continuous monitoring generates vastly more data than episodic measurement, and the statistical analysis plan must account for the multiplicity of data points. Approaches include aggregating data into daily or weekly summary statistics, using area-under-curve methods for time-series data, or employing mixed-effects models that account for within-subject correlation. The OEM partner should provide guidance on data aggregation methods that are appropriate for the ring’s sensor characteristics.
Data quality and completeness monitoring should be built into the study operations. The ring’s cloud platform should provide real-time dashboards showing data completeness per subject, enabling the study coordinator to contact subjects with low adherence and address barriers to wear. Pre-specified data completeness thresholds—typically 70-80% of expected data points—should be defined in the statistical analysis plan, with sensitivity analyses to assess the impact of missing data on study conclusions.
Regulatory Considerations for Smart Ring Data in Submissions
When smart ring data is intended to support regulatory submissions—NDA, BLA, PMA, or 510(k)—the device and the data must meet regulatory standards for quality, reliability, and integrity. The FDA’s 21 CFR Part 11 regulation on electronic records and electronic signatures applies to wearable-generated data used in regulatory submissions.
Device validation documentation is a regulatory requirement. The OEM partner should provide a validation package that includes: sensor accuracy testing against reference standards, data integrity testing (verifying that data is not corrupted or lost during transmission and storage), cybersecurity testing (verifying that data is protected from unauthorized access or modification), and software validation per IEC 62304 for the firmware and cloud platform components.
Data provenance and audit trail capabilities are essential for regulatory submissions. Every data point should be traceable to the specific device, subject, and timestamp, with a complete audit trail of any data modifications, exclusions, or transformations. The cloud platform should support 21 CFR Part 11-compliant electronic signatures, audit logs, and data export in formats suitable for submission to regulatory agencies (SAS transport files, CDISC SDTM format).
For studies conducted under an Investigational Device Exemption (IDE) or as part of a device premarket submission, the ring itself may be considered an investigational device. The OEM partner should support the sponsor in preparing the IDE application, including device description, risk analysis, and clinical protocol documentation. Smart ring OEM partners with experience in regulated clinical research can significantly accelerate the regulatory submission timeline.
OEM Smart Ring Customization for Research Applications
Clinical research applications require customization beyond what is typical for commercial smart ring deployments. The research-grade ring must provide raw sensor data access, configurable sampling protocols, and GCP-compliant data management.
Raw data access is the most critical research customization. Unlike consumer rings that provide only processed metrics (e.g., heart rate = 72 bpm), research rings must expose the raw PPG waveform, accelerometer streams, and temperature readings. This enables researchers to apply their own signal processing algorithms, develop novel digital biomarkers, and validate the device’s measurements independently. The OEM partner should provide an SDK with APIs for raw data streaming, offline data download, and integration with research data platforms like REDCap, LabKey, or Medidata.
Configurable sampling protocols enable researchers to optimize the trade-off between data richness and battery life for their specific study. A 24-hour study might use continuous high-frequency sampling, while a 12-month observational study might use intermittent sampling with periodic high-resolution windows. The OEM partner should provide a configuration tool that allows researchers to define sampling schedules, sensor activation patterns, and data transmission intervals without modifying firmware.
Smart ring customization for research also includes compliance with Good Clinical Practice (GCP) guidelines. The device management platform should support investigator blinding (where the ring provides no feedback to the subject that could influence behavior), subject compliance monitoring (with automated alerts for non-wear), and data locking at study completion. The OEM partner should provide a GCP compliance statement and support sponsor audits of the device and data management systems.
For pharmaceutical companies and CROs building digital research capabilities, the smart ring OEM partner is more than a hardware supplier—they are a technology partner enabling the digital transformation of clinical research. The partnership should include joint development of digital biomarkers, co-publication of validation studies, and ongoing collaboration to advance the science of wearable-enabled clinical trials. As the evidence base for digital endpoints grows, the smart ring manufacturers who invest in research-grade capabilities will be the preferred partners for the pharmaceutical industry.